{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:05Z","timestamp":1793459645106,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41375-025-02649-9","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:11:09Z","timestamp":1748841069000},"page":"2061-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-9547","authenticated-orcid":false,"given":"Simone","family":"Cesaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-3245","authenticated-orcid":false,"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-4602","authenticated-orcid":false,"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-0423","authenticated-orcid":false,"given":"Hans H.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-4110","authenticated-orcid":false,"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-0971","authenticated-orcid":false,"given":"Varun","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-119X","authenticated-orcid":false,"given":"Jan","family":"Styczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-2272","authenticated-orcid":false,"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-2562","authenticated-orcid":false,"given":"Jose Luis","family":"Pinana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6758-6104","authenticated-orcid":false,"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Herman","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ECIL-10","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-5779","authenticated-orcid":false,"given":"Rafael","family":"de la Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2649_CR1","doi-asserted-by":"publisher","unstructured":"Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 2022. https:\/\/doi.org\/10.1038\/s41375-022-01578-1.","DOI":"10.1038\/s41375-022-01578-1"},{"key":"2649_CR2","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","volume":"37","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2023;37:1933\u20138.","journal-title":"Leukemia"},{"key":"2649_CR3","doi-asserted-by":"publisher","first-page":"1125824","DOI":"10.3389\/fimmu.2023.1125824","volume":"14","author":"P Ljungman","year":"2023","unstructured":"Ljungman P, Tridello G, Pi\u00f1ana JL, Ciceri F, Sengeloev H, Kulagin A, et al. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Front Immunol. 2023;14:1125824.","journal-title":"Front Immunol"},{"key":"2649_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijid.2023.10.013","volume":"137","author":"G Rossi","year":"2023","unstructured":"Rossi G, Salmanton-Garc\u00eda J, Cattaneo C, Marchesi F, D\u00e1vila-Valls J, Mart\u00edn-P\u00e9rez S, et al. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. Int J Infect Dis. 2023;137:98\u2013110.","journal-title":"Int J Infect Dis"},{"key":"2649_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/ejh.14108","volume":"111","author":"LC Lund","year":"2023","unstructured":"Lund LC, Rahbek MT, Brown P, Obel N, Hallas J, Frederiksen H. Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study. Eur J Haematol. 2023;111:946\u201350.","journal-title":"Eur J Haematol"},{"key":"2649_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.18690","volume":"201","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Testi D, Russo C, Balletto E, Sepulcri C, Bussini L, et al. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders. Br J Haematol. 2023;201:628\u201339.","journal-title":"Br J Haematol"},{"key":"2649_CR7","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/s41375-024-02336-1","volume":"38","author":"AM Spanjaart","year":"2024","unstructured":"Spanjaart AM, Ljungman P, Tridello G, Schwartz J, Martinez-Cibri\u00e1n N, Barba P, et al. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2024;38:1985\u201391.","journal-title":"Leukemia"},{"key":"2649_CR8","doi-asserted-by":"publisher","first-page":"1389345","DOI":"10.3389\/fonc.2024.1389345","volume":"14","author":"JL Pi\u00f1ana","year":"2024","unstructured":"Pi\u00f1ana JL, Vazquez L, Heras I, Aiello TF, L\u00f3pez-Corral L, Arroyo I, et al. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. Front Oncol. 2024;14:1389345.","journal-title":"Front Oncol"},{"key":"2649_CR9","unstructured":"Resources. https:\/\/ecil-leukaemia.com\/en\/resources\/resources-ecil (accessed 10 Feb2022)."},{"key":"2649_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18:53\u201367.","journal-title":"Clin Microbiol Infect"},{"key":"2649_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.4103\/jcrt.JCRT_782_23","volume":"19","author":"J Wang","year":"2023","unstructured":"Wang J, Shao L, Liang J, Wu Q, Zhu B, Deng Q, et al. Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2. J Cancer Res Ther. 2023;19:1495\u20131500.","journal-title":"J Cancer Res Ther"},{"key":"2649_CR12","doi-asserted-by":"publisher","first-page":"e14332","DOI":"10.1111\/tid.14332","volume":"26","author":"D Neofytos","year":"2024","unstructured":"Neofytos D, Khanna N. How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients. Transpl Infect Dis. 2024;26:e14332.","journal-title":"Transpl Infect Dis"},{"key":"2649_CR13","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.3390\/cancers15164108","volume":"15","author":"AP Gandhi","year":"2023","unstructured":"Gandhi AP, Lee CJ. Telemedicine in hematopoietic cell transplantation and chimeric antigen receptor-T cell therapy. Cancers (Basel). 2023;15:4108.","journal-title":"Cancers (Basel)"},{"key":"2649_CR14","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.4103\/jfmpc.jfmpc_830_24","volume":"13","author":"M Salman","year":"2024","unstructured":"Salman M, Kimball R, Bromley S, Belleville T, Jabbar ABA, Mirza M, et al. Telemedicine: Future of the healthcare system and its impact on patient satisfaction: A literature review. J Fam Med Prim Care. 2024;13:4810\u20134.","journal-title":"J Fam Med Prim Care"},{"key":"2649_CR15","doi-asserted-by":"publisher","first-page":"1184956","DOI":"10.3389\/fimmu.2023.1184956","volume":"14","author":"C Oltolini","year":"2023","unstructured":"Oltolini C, Acerbis A, Orofino G, Racca S, Noviello M, Dispinseri S, et al. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia. Front Immunol. 2023;14:1184956.","journal-title":"Front Immunol"},{"key":"2649_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciad181","volume":"77","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77:280\u20136.","journal-title":"Clin Infect Dis"},{"key":"2649_CR17","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/jac\/dkad105","volume":"78","author":"T-F Aiello","year":"2023","unstructured":"Aiello T-F, Puerta-Alcalde P, Chumbita M, Lopera C, Monz\u00f3 P, Cortes A, et al. Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals. J Antimicrob Chemother. 2023;78:1454\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"2649_CR18","doi-asserted-by":"publisher","first-page":"1207225","DOI":"10.3389\/fcimb.2023.1207225","volume":"13","author":"W Guo","year":"2023","unstructured":"Guo W, Zheng Y, Feng S. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. Front Cell Infect Microbiol. 2023;13:1207225.","journal-title":"Front Cell Infect Microbiol"},{"key":"2649_CR19","doi-asserted-by":"crossref","unstructured":"Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis 2021; ciab048.","DOI":"10.1093\/cid\/ciab048"},{"key":"2649_CR20","doi-asserted-by":"publisher","first-page":"e0007223","DOI":"10.1128\/cmr.00072-23","volume":"37","author":"ES Theel","year":"2024","unstructured":"Theel ES, Kirby JE, Pollock NR. Testing for SARS-CoV-2: lessons learned and current use cases. Clin Microbiol Rev. 2024;37:e0007223.","journal-title":"Clin Microbiol Rev"},{"key":"2649_CR21","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/j.jinf.2022.02.022","volume":"84","author":"P de Michelena","year":"2022","unstructured":"de Michelena P, Torres I, Ramos-Garc\u00eda \u00c1, Gozalbes V, Ruiz N, Sanmart\u00edn A, et al. Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant. J Infect. 2022;84:e64\u2013e66.","journal-title":"J Infect"},{"key":"2649_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02006-22","volume":"10","author":"K Leuzinger","year":"2022","unstructured":"Leuzinger K, Roloff T, Egli A, Hirsch HH. Impact of SARS-CoV-2 Omicron on Rapid Antigen Testing Developed for Early-Pandemic SARS-CoV-2 Variants. Microbiol Spectr. 2022;10:e0200622.","journal-title":"Microbiol Spectr"},{"key":"2649_CR23","doi-asserted-by":"publisher","first-page":"e0282150","DOI":"10.1371\/journal.pone.0282150","volume":"18","author":"J-M Schwob","year":"2023","unstructured":"Schwob J-M, Miauton A, Petrovic D, Perdrix J, Senn N, Gouveia A, et al. Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: A prospective comparative clinical trial. PLoS One. 2023;18:e0282150.","journal-title":"PLoS One"},{"key":"2649_CR24","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1002\/jmv.26731","volume":"93","author":"K Leuzinger","year":"2021","unstructured":"Leuzinger K, Gosert R, S\u00f8gaard KK, Naegele K, Bielicki J, Roloff T, et al. Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. J Med Virol. 2021;93:2374\u201384.","journal-title":"J Med Virol"},{"key":"2649_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02180-0","volume":"29","author":"W Shu","year":"2024","unstructured":"Shu W, Yang Q, Le J, Cai Q, Dai H, Luo L, et al. Analysis of coinfections in patients with hematologic malignancies and COVID-19 by next-generation sequencing of bronchoalveolar lavage fluid. Eur J Med Res. 2024;29:576.","journal-title":"Eur J Med Res"},{"key":"2649_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1287496","volume":"13","author":"X Zhou","year":"2023","unstructured":"Zhou X, Wu X, Chen Z, Cui X, Cai Y, Liu Y, et al. Risk factors and the value of microbiological examinations of COVID-19 associated pulmonary aspergillosis in critically ill patients in intensive care unit: the appropriate microbiological examinations are crucial for the timely diagnosis of CAPA. Front Cell Infect Microbiol. 2023;13:1287496.","journal-title":"Front Cell Infect Microbiol"},{"key":"2649_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.12835","volume":"7","author":"LH Fisher","year":"2024","unstructured":"Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, et al. SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024;7:e2412835.","journal-title":"JAMA Netw Open"},{"key":"2649_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/cid\/ciae469","volume":"79","author":"TO Jensen","year":"2024","unstructured":"Jensen TO, Harper K, Gupta S, Liu ST, Dharan NJ, Baker JV, et al. Impact of Baseline SARS-CoV-2 Load in Plasma and Upper Airways on the Incidence of Acute Extrapulmonary Complications of COVID-19: A Multicentric, Prospective, Cohort Study. Clin Infect Dis. 2024;79:1394\u2013403.","journal-title":"Clin Infect Dis"},{"key":"2649_CR29","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciad780","volume":"78","author":"NR Aggarwal","year":"2024","unstructured":"Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, et al. Viral and host factors are associated with mortality in hospitalized patients with COVID-19. Clin Infect Dis. 2024;78:1490\u2013503.","journal-title":"Clin Infect Dis"},{"key":"2649_CR30","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","volume":"5","author":"Z Raglow","year":"2024","unstructured":"Raglow Z, Surie D, Chappell JD, Zhu Y, Martin ET, Kwon JH, et al. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe. 2024;5:e235\u2013e246.","journal-title":"Lancet Microbe"},{"key":"2649_CR31","first-page":"147","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21:147\u201361.","journal-title":"Nat Rev Microbiol"},{"key":"2649_CR32","doi-asserted-by":"publisher","first-page":"e0306891","DOI":"10.1371\/journal.pone.0306891","volume":"19","author":"H Koshimichi","year":"2024","unstructured":"Koshimichi H, Hisaka A. Analyzing the worldwide progression of COVID-19 cases and deaths using nonlinear mixed-effects model. PLoS One. 2024;19:e0306891.","journal-title":"PLoS One"},{"key":"2649_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s15010-023-02169-7","volume":"52","author":"T Lahmer","year":"2024","unstructured":"Lahmer T, Salmanton-Garc\u00eda J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024;52:1125\u201341.","journal-title":"Infection"},{"key":"2649_CR34","doi-asserted-by":"crossref","unstructured":"Salmanton-Garc\u00eda J, Marchesi F, Farina F, Weinbergerov\u00e1 B, Itri F, D\u00e1vila-Valls J et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine 2024; 71: 102553.","DOI":"10.1016\/j.eclinm.2024.102553"},{"key":"2649_CR35","unstructured":"COVID-19 medicines | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines (accessed 8 Mar2025)."},{"key":"2649_CR36","doi-asserted-by":"publisher","first-page":"126054","DOI":"10.1016\/j.vaccine.2024.05.081","volume":"42","author":"AC Sherman","year":"2024","unstructured":"Sherman AC, van Haren SD, Borberg E, Swank Z, Aleissa M, Tong A, et al. Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series. Vaccine. 2024;42:126054.","journal-title":"Vaccine"},{"key":"2649_CR37","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/infdis\/jiad174","volume":"228","author":"VG Hall","year":"2023","unstructured":"Hall VG, Teh BW. COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future. J Infect Dis. 2023;228:S55\u2013S69.","journal-title":"J Infect Dis"},{"key":"2649_CR38","doi-asserted-by":"crossref","unstructured":"Body A, Lal L, Srihari S, MacIntyre CR, Buttery J, Ahern ES et al. Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer. Vaccine 2024; : 126547.","DOI":"10.2139\/ssrn.4951802"},{"key":"2649_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bjh.19126","volume":"204","author":"L Kevli\u010dius","year":"2024","unstructured":"Kevli\u010dius L, \u0160ablauskas K, Maneikis K, Juozapait\u0117 D, Ringelevi\u010di\u016bt\u0117 U, Vaitek\u0117nait\u0117 V, et al. Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS-CoV-2 Omicron in patients with haematological malignancies: A national prospective cohort study. Br J Haematol. 2024;204:497\u2013506.","journal-title":"Br J Haematol"},{"key":"2649_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.31662\/jmaj.2023-0171","volume":"7","author":"A Das Barshan","year":"2024","unstructured":"Das Barshan A, Matsumoto-Takahashi ELA. Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis. JMA J. 2024;7:153\u201371.","journal-title":"JMA J"},{"key":"2649_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ejh.13986","volume":"111","author":"LD Heftdal","year":"2023","unstructured":"Heftdal LD, Hamm SR, P\u00e9rez-Al\u00f3s L, Madsen JR, Armenteros JJA, Fogh K, et al. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies. Eur J Haematol. 2023;111:229\u201339.","journal-title":"Eur J Haematol"},{"key":"2649_CR42","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1182\/bloodadvances.2023010349","volume":"7","author":"T Meejun","year":"2023","unstructured":"Meejun T, Srisurapanont K, Manothummetha K, Thongkam A, Mejun N, Chuleerarux N, et al. Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis. Blood Adv. 2023;7:5624\u201336.","journal-title":"Blood Adv"},{"key":"2649_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/cid\/ciae291","volume":"79","author":"JA Hill","year":"2024","unstructured":"Hill JA, Martens MJ, Young J-AH, Bhavsar K, Kou J, Chen M, et al. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T-cell therapy: a prospective, multicenter, observational study. Clin Infect Dis. 2024;79:542\u201354.","journal-title":"Clin Infect Dis"},{"key":"2649_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10238-024-01381-5","volume":"24","author":"HJ Ng","year":"2024","unstructured":"Ng HJ, Alata MK, Nguyen QT, Huynh Duc Vinh P, Tan JY, Wong CL. Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights. Clin Exp Med. 2024;24:119.","journal-title":"Clin Exp Med"},{"key":"2649_CR45","doi-asserted-by":"publisher","first-page":"e2332813","DOI":"10.1001\/jamanetworkopen.2023.32813","volume":"6","author":"T Gonen","year":"2023","unstructured":"Gonen T, Barda N, Asraf K, Joseph G, Weiss-Ottolenghi Y, Doolman R, et al. Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines. JAMA Netw Open. 2023;6:e2332813.","journal-title":"JAMA Netw Open"},{"key":"2649_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105103","volume":"103","author":"D Pattinson","year":"2024","unstructured":"Pattinson D, Jester P, Gu C, Guan L, Armbrust T, Petrie JG, et al. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses. EBioMedicine. 2024;103:105103.","journal-title":"EBioMedicine"},{"key":"2649_CR47","doi-asserted-by":"publisher","first-page":"105385","DOI":"10.1016\/j.ebiom.2024.105385","volume":"109","author":"P Chen","year":"2024","unstructured":"Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID. EBioMedicine. 2024;109:105385.","journal-title":"EBioMedicine"},{"key":"2649_CR48","unstructured":"Clinical Guidance for COVID-19 Vaccination | CDC. 2025.https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html (accessed 8 Mar2025)."},{"key":"2649_CR49","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29:438.e1\u2013438.e16.","journal-title":"Transplant Cell Ther"},{"key":"2649_CR50","doi-asserted-by":"publisher","first-page":"1174289","DOI":"10.3389\/fimmu.2023.1174289","volume":"14","author":"ML H\u00fctter-Kr\u00f6nke","year":"2023","unstructured":"H\u00fctter-Kr\u00f6nke ML, Neagoie A, Blau IW, Wais V, Vuong L, Gantner A, et al. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Front Immunol. 2023;14:1174289.","journal-title":"Front Immunol"},{"key":"2649_CR51","unstructured":"CDC. Staying Up to Date with COVID-19 Vaccines. COVID-19. 2025.https:\/\/www.cdc.gov\/covid\/vaccines\/stay-up-to-date.html (accessed 8 Mar2025)."},{"key":"2649_CR52","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42:1699\u2013721.","journal-title":"J Clin Oncol"},{"key":"2649_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74712-x","volume":"14","author":"S Einarsdottir","year":"2024","unstructured":"Einarsdottir S, Al-Dury S, Fridriksson E, Andius LD, Wang H, Sharba S, et al. Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation. Sci Rep. 2024;14:24749.","journal-title":"Sci Rep."},{"key":"2649_CR54","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/bjh.19780","volume":"205","author":"M Tsoutsoukis","year":"2024","unstructured":"Tsoutsoukis M, Anthias C, Easdale S, Nicholson E. Re-vaccination against SARS-CoV-2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates. Br J Haematol. 2024;205:1720\u20136.","journal-title":"Br J Haematol"},{"key":"2649_CR55","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.3390\/curroncol31090393","volume":"31","author":"S Claveau","year":"2024","unstructured":"Claveau S, Mahmood F, Amir B, Kwan JJW, White C, Vipond J, et al. COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19. Curr Oncol. 2024;31:5330\u201343.","journal-title":"Curr Oncol"},{"key":"2649_CR56","unstructured":"CDC. Infection Control Guidance: SARS-CoV-2. COVID-19. 2024.https:\/\/www.cdc.gov\/covid\/hcp\/infection-control\/index.html (accessed 8 Mar2025)."},{"key":"2649_CR57","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1093\/jac\/dkae351","volume":"79","author":"H Pinargote-Celorio","year":"2024","unstructured":"Pinargote-Celorio H, Moreno-P\u00e9rez \u00d3, Gonz\u00e1lez-De-La-Aleja P, Llenas-Garc\u00eda J, Mart\u00ednez P\u00e9rez-Crespo PM, Rodr\u00edguez-D\u00edaz J-C, et al. Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score\u2013adjusted retrospective cohort study. Journal Antimicrobial Chemother. 2024;79:3248\u201353.","journal-title":"Journal Antimicrobial Chemother"},{"key":"2649_CR58","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76:e342\u2013e349.","journal-title":"Clin Infect Dis"},{"key":"2649_CR59","doi-asserted-by":"publisher","first-page":"e13264","DOI":"10.1111\/irv.13264","volume":"18","author":"TF Aiello","year":"2024","unstructured":"Aiello TF, Peyrony O, Chumbita M, Monz\u00f3 P, Lopera C, Puerta-Alcalde P, et al. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies. Influenza Other Respir Viruses. 2024;18:e13264.","journal-title":"Influenza Other Respir Viruses"},{"key":"2649_CR60","doi-asserted-by":"crossref","unstructured":"Rawson JMO, Donaldson EF, O\u2019Rear JJ, Harrington PR Independent FDA Analyses of Nirmatrelvir\/Ritonavir Resistance in the Phase 2\/3 Trials EPIC-HR and EPIC-SR. Clin Infect Dis 2024; : ciae615.","DOI":"10.1093\/cid\/ciae615"},{"key":"2649_CR61","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2024.08.004","volume":"46","author":"E Mozaffari","year":"2024","unstructured":"Mozaffari E, Chandak A, Ustianowski A, Rivera CG, Ahuja N, Jiang H, et al. Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients. Clin Ther. 2024;46:778\u201384.","journal-title":"Clin Ther"},{"key":"2649_CR62","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/jac\/dkae237","volume":"79","author":"E Gras","year":"2024","unstructured":"Gras E, Aiello TF, Chumbita M, Gallardo-Pizarro A, Monz\u00f3-Gallo P, Teij\u00f3n-Lumbreras C, et al. Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes. J Antimicrob Chemother. 2024;79:2364\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2649_CR63","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3390\/v15102066","volume":"15","author":"JL Pi\u00f1ana","year":"2023","unstructured":"Pi\u00f1ana JL, Heras I, Aiello TF, Garc\u00eda-Cadenas I, Vazquez L, Lopez-Jimenez J, et al. Remdesivir or Nirmatrelvir\/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. 2023;15:2066.","journal-title":"Viruses"},{"key":"2649_CR64","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1093\/cid\/ciae510","volume":"79","author":"E Mozaffari","year":"2024","unstructured":"Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Amin AN, et al. Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era. Clin Infect Dis. 2024;79:S149\u2013S159.","journal-title":"Clin Infect Dis"},{"key":"2649_CR65","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","volume":"228","author":"C Hedskog","year":"2023","unstructured":"Hedskog C, Rodriguez L, Roychoudhury P, Huang M-L, Jerome KR, Hao L, et al. Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1). J Infect Dis. 2023;228:1263\u201373.","journal-title":"J Infect Dis"},{"key":"2649_CR66","doi-asserted-by":"publisher","first-page":"e0019822","DOI":"10.1128\/aac.00198-22","volume":"66","author":"L Checkmahomed","year":"2022","unstructured":"Checkmahomed L, Carbonneau J, Du Pont V, Riola NC, Perry JK, Li J, et al. In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance. Antimicrob Agents Chemother. 2022;66:e0019822.","journal-title":"Antimicrob Agents Chemother"},{"key":"2649_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45641-0","volume":"15","author":"JF Standing","year":"2024","unstructured":"Standing JF, Buggiotti L, Guerra-Assuncao JA, Woodall M, Ellis S, Agyeman AA, et al. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Nat Commun. 2024;15:1652.","journal-title":"Nat Commun"},{"key":"2649_CR68","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S2666-5247(23)00393-2","volume":"5","author":"NM Fountain-Jones","year":"2024","unstructured":"Fountain-Jones NM, Vanhaeften R, Williamson J, Maskell J, Chua I-LJ, Charleston M, et al. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study. Lancet Microbe. 2024;5:e452\u2013e458.","journal-title":"Lancet Microbe"},{"key":"2649_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijid.2023.09.021","volume":"137","author":"D Focosi","year":"2023","unstructured":"Focosi D, Maggi F, D\u2019Abramo A, Nicastri E, Sullivan DJ. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients. Int J Infect Dis. 2023;137:55\u201359.","journal-title":"Int J Infect Dis"},{"key":"2649_CR70","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/QCO.0000000000001070","volume":"37","author":"C Sepulcri","year":"2024","unstructured":"Sepulcri C, Bartalucci C, Mikulska M. Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients. Curr Opin Infect Dis. 2024;37:506\u201317.","journal-title":"Curr Opin Infect Dis"},{"key":"2649_CR71","unstructured":"Public-health advice on COVID-19 medicines | European Medicines Agency (EMA). 2020. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines\/public-health-advice-covid-19-medicines (accessed 8 Mar2025)."},{"key":"2649_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v10i1.752","volume":"10","author":"D Planas","year":"2024","unstructured":"Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Pathog Immun. 2024;10:1\u201311.","journal-title":"Pathog Immun"},{"key":"2649_CR73","unstructured":"CDC. Types of COVID-19 Treatment. COVID-19. 2024.https:\/\/www.cdc.gov\/covid\/treatment\/index.html (accessed 8 Mar2025)."},{"key":"2649_CR74","unstructured":"Kavigale | European Medicines Agency (EMA). 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kavigale (accessed 8 Mar2025)."},{"key":"2649_CR75","doi-asserted-by":"publisher","first-page":"2387221","DOI":"10.1080\/21645515.2024.2387221","volume":"20","author":"P Loubet","year":"2024","unstructured":"Loubet P, Gaborit B, Salpin M, Gardeney H, Benotmane I, Systchenko T. Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France. Hum Vaccin Immunother. 2024;20:2387221.","journal-title":"Hum Vaccin Immunother"},{"key":"2649_CR76","doi-asserted-by":"publisher","first-page":"101668","DOI":"10.1016\/j.xcrm.2024.101668","volume":"5","author":"WN Voss","year":"2024","unstructured":"Voss WN, Mallory MA, Byrne PO, Marchioni JM, Knudson SA, Powers JM, et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Rep. Med. 2024;5:101668.","journal-title":"Cell Rep. Med"},{"key":"2649_CR77","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/cid\/ciad066","volume":"76","author":"EM Bloch","year":"2023","unstructured":"Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, et al. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019. Clin Infect Dis. 2023;76:2018\u201324.","journal-title":"Clin Infect Dis"},{"key":"2649_CR78","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.mayocpiqo.2023.09.001","volume":"7","author":"JW Senefeld","year":"2023","unstructured":"Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, et al. Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clin Proc Innov Qual Outcomes. 2023;7:499\u2013513.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2649_CR79","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cmi.2024.07.020","volume":"30","author":"M Franchini","year":"2024","unstructured":"Franchini M, Cruciani M, Mengoli C, Casadevall A, Glingani C, Joyner MJ, et al. Convalescent plasma and predictors of mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30:1514\u201322.","journal-title":"Clin Microbiol Infect"},{"key":"2649_CR80","doi-asserted-by":"publisher","first-page":"e2250647","DOI":"10.1001\/jamanetworkopen.2022.50647","volume":"6","author":"JW Senefeld","year":"2023","unstructured":"Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6:e2250647.","journal-title":"JAMA Netw Open"},{"key":"2649_CR81","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ijc.34988","volume":"155","author":"M Janssen","year":"2024","unstructured":"Janssen M, Leo A, Wolf C, Stenzinger M, Bartenschlager M, Brandt J, et al. Treatment of chronic COVID-19 with convalescent\/postvaccination plasma in patients with hematologic malignancies. Int J Cancer. 2024;155:618\u201326.","journal-title":"Int J Cancer"},{"key":"2649_CR82","doi-asserted-by":"publisher","first-page":"e29603","DOI":"10.1002\/jmv.29603","volume":"96","author":"M Destremau","year":"2024","unstructured":"Destremau M, Chaussade H, Hemar V, Beguet M, Bellecave P, Blanchard E, et al. Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study. J Med Virol. 2024;96:e29603.","journal-title":"J Med Virol"},{"key":"2649_CR83","doi-asserted-by":"publisher","first-page":"e0040024","DOI":"10.1128\/mbio.00400-24","volume":"15","author":"JG Ripoll","year":"2024","unstructured":"Ripoll JG, Tulledge-Scheitel SM, Stephenson AA, Ford S, Pike ML, Gorman EK, et al. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19. mBio. 2024;15:e0040024.","journal-title":"mBio"},{"key":"2649_CR84","unstructured":"Research C for BE and. Investigational COVID-19 Convalescent Plasma. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-covid-19-convalescent-plasma (accessed 8 Mar2025)."},{"key":"2649_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49756-2","volume":"15","author":"LPA Neyton","year":"2024","unstructured":"Neyton LPA, Patel RK, Sarma A, UCSF COMET Consortium, Willmore A, Haller SC, et al. Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19. Nat Commun. 2024;15:5483.","journal-title":"Nat Commun"},{"key":"2649_CR86","doi-asserted-by":"publisher","first-page":"1143350","DOI":"10.3389\/fimmu.2023.1143350","volume":"14","author":"AA Chimote","year":"2023","unstructured":"Chimote AA, Alshwimi AO, Chirra M, Gawali VS, Powers-Fletcher MV, Hudock KM, et al. Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. Front Immunol. 2023;14:1143350.","journal-title":"Front Immunol"},{"key":"2649_CR87","doi-asserted-by":"publisher","first-page":"108121","DOI":"10.1016\/j.intimp.2021.108121","volume":"100","author":"H Li","year":"2021","unstructured":"Li H, Yan B, Gao R, Ren J, Yang J. Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies. Int Immunopharmacol. 2021;100:108121.","journal-title":"Int Immunopharmacol"},{"key":"2649_CR88","doi-asserted-by":"publisher","first-page":"2102532","DOI":"10.1183\/13993003.02532-2021","volume":"60","author":"K Crothers","year":"2022","unstructured":"Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, et al. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Eur Respir J. 2022;60:2102532.","journal-title":"Eur Respir J"},{"key":"2649_CR89","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.3324\/haematol.2024.285875","volume":"109","author":"TF Aiello","year":"2024","unstructured":"Aiello TF, Salmanton-Garcia J, Marchesi F, Weinbergerova B, Glenthoj A, Van Praet J, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry. Haematologica. 2024;109:2693\u20132700.","journal-title":"Haematologica"},{"key":"2649_CR90","volume":"54","author":"Y Jafari Abarghan","year":"2024","unstructured":"Jafari Abarghan Y, Heiat M, Jahangiri A, Hossein Peypar M, Abdorrashidi M, Tohidinia A, et al. Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2024;54:101483.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2649_CR91","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmi.2023.12.028","volume":"30","author":"DA Sweeney","year":"2024","unstructured":"Sweeney DA, Lobo SM, P\u00f3voa P, Kalil AC. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence. Clin Microbiol Infect. 2024;30:611\u201368.","journal-title":"Clin Microbiol Infect"},{"key":"2649_CR92","doi-asserted-by":"publisher","unstructured":"Aso S, Ono S, Michihata N, Uemura K, Yasunaga H Differences in patient characteristics, treatments, and mortality of COVID-19 between 2022 and 2020-2021. Jpn J Infect Dis 2024. https:\/\/doi.org\/10.7883\/yoken.JJID.2024.272.","DOI":"10.7883\/yoken.JJID.2024.272"},{"key":"2649_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68013-6","volume":"14","author":"A Goldstein","year":"2024","unstructured":"Goldstein A, Neuberger A, Darawsha YQ, Hussein K, Shafat T, Grupel D, et al. Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement. Sci Rep. 2024;14:16985.","journal-title":"Sci Rep"},{"key":"2649_CR94","unstructured":"Research C for DE and FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19. FDA 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-gohibic-vilobelimab-injection-treatment-covid-19 (accessed 8 Mar2025)."},{"key":"2649_CR95","unstructured":"Gohibic | European Medicines Agency (EMA). 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gohibic (accessed 8 Mar2025)."},{"key":"2649_CR96","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10:1137\u201346.","journal-title":"Lancet Respir Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02649-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02649-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02649-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:40:13Z","timestamp":1757184013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02649-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2649"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02649-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}